Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$14.86 USD
-0.35 (-2.30%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $14.85 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Stoke Therapeutics, Inc. [STOK]
Reports for Purchase
Showing records 41 - 60 ( 92 total )
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It Is All About Fine-Tuning the STK-001 Dosing to Achieve Maximum Efficacy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
What Will We Learn From MONARCH? Looking Ahead to 2H22 STK-001 Update
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As STK-001 Makes Progress, MECP2 and SYNGAP1 Collaboration Expands TANGO?s Scope
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MONARCH?s Flight Path On The Right Direction
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking Past The Pain Of The Macro, We See a Lot To Like With STK-001
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Stoke Makes Progress Across Pipeline; Reit Buy and $70 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
My Kind Of Town - Detailed MONARCH Data Next Up At AES in Chicago
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MONARCH Interim Data Encouraging with Early Trends in Efficacy - Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dancin'' In September - MONARCH Interim Data Arrives
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Spotlight on MONARCH?Our Insights into Dose Selection and Safety
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A